Maravai LifeSciences Holdings, Inc. (MRVI)

NMS – Real Time Price. Currency in USD

4.66

-0.08 (-1.69%)

At close: May 12, 2026, 4:00 PM EDT

4.66

0.00 (0.00%)

After-hours: May 12, 2026, 5:42 PM EDT

08.05.2026

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.

07.05.2026

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.08 per share a year ago.

07.05.2026

Maravai LifeSciences Reports First Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million; Returned to positive free cash flow, generating $4.2 million in the quarter; and Inc.

06.05.2026

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Maravai LifeSciences (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

30.04.2026

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Baxter International (BAX) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago.

20.04.2026

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2026 financial and operating results after the market close on Thursday, May 7, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-5172 or 1-203-518-9856 and reference Marava.

26.02.2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

07.05.2026

Maravai LifeSciences Reports First Quarter 2026 Financial Results

25.02.2026

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of.

06.11.2025

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million “We exited the third quarter confident about the future of our business. Cygnus co.

29.10.2025

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders

Allegedly, Maravai misstated revenue and overstated goodwill due to weak internal controls, causing a 22% stock drop after delaying its earnings report.

Maravai LifeSciences Holdings, Inc. (MRVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Maravai LifeSciences Holdings, Inc. (MRVI)

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Reports First Quarter 2026 Financial Results

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

Maravai LifeSciences Reports First Quarter 2026 Financial Results

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Reports First Quarter 2026 Financial Results

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

Maravai LifeSciences Reports First Quarter 2026 Financial Results

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders

Search stocks

Maravai LifeSciences Holdings, Inc. (MRVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Maravai LifeSciences Holdings, Inc. (MRVI)

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Reports First Quarter 2026 Financial Results

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

Maravai LifeSciences Reports First Quarter 2026 Financial Results

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Reports First Quarter 2026 Financial Results

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

Maravai LifeSciences Reports First Quarter 2026 Financial Results

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders